In short
BCX17725 is an investigational substance being studied for the treatment of Netherton syndrome, a rare genetic skin condition. A single authorised Phase 1 trial (NCT06539507) is currently planned to evaluate its safety, tolerability, pharmacokinetics, and immunogenicity in 12 adult and adolescent participants. The study will assess changes in the Ichthyosis Area and Severity Index (IASI) score over 12 weeks of treatment.
Key points
- BCX17725 is an investigational substance with no marketing authorisation.
- The only registered trial is a Phase 1 study in Netherton syndrome.
- The trial plans to enrol 12 adult and adolescent participants.
- BCX17725 is being studied for administration by intravenous, subcutaneous, or intramuscular routes.
- The study measures safety, tolerability, pharmacokinetics, and immunogenicity over 12 weeks.
- The trial is currently authorised but not yet recruiting.
What is BCX17725?
BCX17725 is an investigational substance currently being studied in a clinical trial for Netherton syndrome. It has not yet received marketing authorisation, meaning it is not available as a prescribed medicine. The substance is being developed to address the needs of adult and adolescent participants with this rare genetic skin condition. No trade names or other development codes are listed in the registry data.
How does BCX17725 work?
The registry record for the Phase 1 trial does not describe a specific molecular target or mechanism of action for BCX17725. The study is designed to characterise how the substance behaves in the body, including its pharmacokinetics (how the drug is absorbed, distributed, metabolised, and eliminated) and immunogenicity (whether the body develops an immune response to the drug).
Which conditions is it studied for?
- Netherton syndrome — a rare inherited skin disorder characterised by red, scaly skin, hair shaft abnormalities, and an impaired skin barrier. The trial focuses on adult and adolescent participants with this condition.
How is BCX17725 given?
According to the trial record, BCX17725 is being studied for administration by intravenous, subcutaneous, or intramuscular routes. The pharmaceutical form is not specified in the registry data. The exact route and dosing schedule for individual participants would be determined by the study protocol.
What do the clinical trials show?
There is currently one authorised Phase 1 trial of BCX17725 listed in the registry. The trial, identified as NCT06539507, is an interventional study with a planned enrolment of 12 participants. The study status is authorised, meaning it has received regulatory approval but has not yet started recruiting. The trial is designed to evaluate the therapeutic potential of BCX17725 in adult and adolescent participants with Netherton syndrome over a 12-week treatment period.
The primary outcome measures include the change from baseline in the Ichthyosis Area and Severity Index (IASI) score at Week 12, which measures the extent and severity of skin scaling and redness. The study will also assess the incidence of treatment-emergent adverse events (TEAEs) through the end of the study, and the concentration of BCX17725 in serum over time. These measures help researchers understand both the potential benefit of the treatment and its safety profile.
What side effects are known?
No side effects or adverse events for BCX17725 are reported in the available registry data or supplementary sources. As this is a Phase 1 trial, the safety evaluation is a primary objective, and the incidence of treatment-emergent adverse events will be monitored throughout the study.